Zobrazeno 1 - 10
of 116
pro vyhledávání: '"Richard W Asinger"'
Publikováno v:
Journal of Thrombosis and Thrombolysis. 55:175-180
Publikováno v:
Journal of thrombosis and thrombolysis.
The SAMe-TT
Autor:
Gautam R. Shroff, Richard W. Asinger
Publikováno v:
Journal of the Minneapolis Heart Institute Foundation. 2:22-25
The prevalence of atrial fibrillation without rheumatic valvular disease, nonvalvular atrial fibrillation (NVAF), increases with age and independently predicts future stroke and systemic embolism. Randomized controlled trials of long-term oral antico
Autor:
Richard W. Asinger, Lesly A. Pearce, Sabe De, Robert G. Hart, Oscar R. Benavente, Nathan G. Chan Smyth, Thalia S. Field
Publikováno v:
Journal of Stroke and Cerebrovascular Diseases. 24:1423-1429
Background: The spectrum, prevalence, and prognosticimplications of abnormal left ventricular geometry (LVG) in patients with lacunar stroke are unknown. We examined the spectrum of LVG and its relationship with vascular risk factors and outcomes aft
Publikováno v:
Circulation: Cardiovascular Quality and Outcomes. 10
Nonvalvular atrial fibrillation (NVAF), atrial fibrillation (AF) without rheumatic valvular disease, is a strong, independent predictor of stroke1 presumably from embolization of left atrial appendage thrombus, suggesting that oral anticoagulant (OAC
Publikováno v:
Congestive Heart Failure and Cardiac Transplantation ISBN: 9783319445755
Ischemic heart disease is a broad term encompassing several closely related syndromes caused by myocardial ischemia, an imbalance between cardiac blood supply perfusion and myocardial oxygen and nutritional requirements.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::693d954c8643ac8076cd657090f7ea38
https://doi.org/10.1007/978-3-319-44577-9_4
https://doi.org/10.1007/978-3-319-44577-9_4
Publikováno v:
Circulation. 134(18)
Publikováno v:
Circulation. 134
Publikováno v:
Clinical Journal of the American Society of Nephrology. 6:2599-2604
The efficacy of adjusted-dose warfarin for prevention of stroke in atrial fibrillation patients with stage 3 chronic kidney disease (CKD) is unknown.Patients with stage 3 CKD participating in the Stroke Prevention in Atrial Fibrillation 3 trials were
Autor:
Alan K. Berger, Patrick H. Pun, Stephanie DeLoach, Eberhard Ritz, Peter A. McCullough, Bertram L. Kasiske, David M. Charytan, Kai-Uwe Eckardt, Rod S. Passman, Javier Díez, Richard W. Asinger, Charles A. Herzog, Robert G. Hart
Publikováno v:
Kidney International. 80(6):572-586
Cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD) is high, and the presence of CKD worsens outcomes of cardiovascular disease (CVD). CKD is associated with specific risk factors. Emerging evidence indicates that the